Order Article Reprints

Stroes CI, Schokker S, Molenaar RJ, Mathôt RAA, Bijlsma MF, van der Woude SO, Belo Pereira JP, Hooijer GKJ, Verhoeven RHA, Cats A, et al. A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers. 2021; 13(4):839. https://doi.org/10.3390/cancers13040839

Stroes, Charlotte I., Sandor Schokker, Remco J. Molenaar, Ron A. A. Mathôt, Maarten F. Bijlsma, Stephanie O. van der Woude, João P. Belo Pereira, Gerrit K. J. Hooijer, Rob H. A. Verhoeven, Annemieke Cats, and et al. 2021. "A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX" Cancers 13, no. 4: 839. https://doi.org/10.3390/cancers13040839

Stroes, C. I., Schokker, S., Molenaar, R. J., Mathôt, R. A. A., Bijlsma, M. F., van der Woude, S. O., Belo Pereira, J. P., Hooijer, G. K. J., Verhoeven, R. H. A., Cats, A., Grootscholten, C., van Sandick, J. W., Creemers, G.-J., Nieuwenhuijzen, G. A. P., Haj Mohammad, N., Ruurda, J. P., Meijer, S. L., Hulshof, M. C. C. M., van Berge Henegouwen, M. I., & van Laarhoven, H. W. M. (2021). A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers, 13(4), 839. https://doi.org/10.3390/cancers13040839